Bharat Immunologicals & Biologicals Limited Receivables

Bharat Immunologicals & Biologicals Limited posts a receivables of $100M as of September 2023. That compares with $280M in the prior-year period — down 63.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Bharat Immunologicals & Biologicals Limited's receivables was $280M. The latest reading is $100M — a 63.9% year-over-year decrease (period ending September 2023). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Bharat Immunologicals & Biologicals Limited's financial statement story. At $100M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BIBCL.BO's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Bharat Immunologicals & Biologicals Limited's other metric pages and overview cover the third.